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Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the
pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the
risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corpo-
rate strategies.Recently, pharmaceutical and biotech-
nology companies have taken an
increased interest in stem cell biology.
The use of stem cells as research tools
has expanded with most of the major
pharmaceutical companies using embry-
onic stem cells (ESCs) or adult stem cells
for internal drug discovery programs.
These internal efforts are often enhanced
through the expertise of external partner-
ships with academics or biotech compa-
nies. The specific use of stem cell-based
tools in conventional drug discovery
programs are varied but based on the
reproducibility of deriving clinically rele-
vant cell types as diverse as sensory
neurons, cardiac myocytes, and pancre-
atic progenitors. Here, rather than focus
on the extensive application of the tech-
nology as tools for drug discovery, we
will discuss the emerging opportunities
for biopharmaceutical companies to
engage in stem cell-based regenerative
medicine. In some instances, the ap-
proach will apply the pharmaceutical
strength in the research and development
of small or largemolecules projects to find
novel therapeutics that modify endoge-
nous stem/progenitor cell fate. For
example, discovery programs that stimu-
late the endogenous activation of cardiac
progenitors for congestive heart failure
(CHF) or myocardial infarction (MI) (Wu
et al., 2004), expansion of pancreatic
islet precursor cells for diabetes (Chen
et al., 2009), or activation or release of
adult progenitors in immune disorders
(Flomenberg et al., 2010). In other cases,
autologous or allogeneic adult stem cells
are used to induce the body’s endoge-
nous regeneration processes in diseased
tissue (e.g., ischemia), typically via the
action of paracrine factors. Finally, theultimate promise of stem cell biology is
cell/tissue replacement therapy. Cell
replacement therapies are anticipated
because of the fact that stem cell deriva-
tives may accurately recapitulate the
normal biology of cells or tissues and
restore function in degenerative diseases.
Therefore, we expect that stem cell-
based therapeutic approaches will
become of particular relevance as phar-
maceutical companies seek opportunities
in disease modification and away from
a focus on purely palliative treatment. As
pharmaceutical companies have been
working for years with global regulatory
agencies and clinical centers to create
strong partnerships, this experience is
a key strength that the pharmaceutical
industry will bring to the Regenerative
Medicine space. In this discussion, we
have focused on large pharmaceutical
companies, (Table 1, note that this anal-
ysis is limited to publicly disclosed infor-
mation), although opportunities for
biotech companies could be stronger in
autologous cell-based therapies.
Since the earliest protocols using
murine ESCs for in vitro differentiation
experiments, it was established that small
molecules, such as retinoic acid and 5-
azacytidine, could be used to direct and
modify stem cell fate. The interest in
developing drug screens for human ESC
differentiation has heightened with better
understanding of developmental path-
ways and the identification of specific
molecules to improve cell differentiation
(reviewed in Ding and Schultz, 2004).
This finding raises the distinct possibility
that small and large molecule (e.g., anti-
bodies, nucleotides, proteins) modifiers
will also be identified that can enhance
endogenous cell and tissue regenera-Cell Stem Ction. As this research paradigm is the
strength of biopharmaceutical compa-
nies, a commitment to regenerative medi-
cine based on combining drug discovery
and stem cell platforms is taking hold
across the industry, through internal
growth or external partnerships (Trounson
et al., 2010, this issue). These new drug
discovery opportunities could be applied
as stand-alone treatments that induce
cell fate (e.g., Erythropoietin) or combined
with existing or emerging stem cell-based
therapies. Furthermore, the advent of
induced pluripotent stem cells (iPSCs)
has created an important new opportunity
for human pluripotent stem cells carrying
specific genetic variants, mutations, and
patient specific cell lines to be used in
drug discovery and personalized regener-
ative medicine. (reviewed in Rowntree
and McNeish, 2010).
In terms of using stem cells as thera-
peutics, 68 cell-based approaches are
listed under clinical development in
a commercial pipeline database. Of these
listings, over 90% are company spon-
sored, with the only large biopharmaceut-
ical companies listed being Teva, Baxter,
and Genzyme (Table 2). However, when
current/completed clinical studies in four
therapeutic areas are evaluated, less
than 20% are company sponsored (and
only three are large company sponsored),
whereas a large number are investigator
initiated studies (Table 2). Pharma’s
involvement may be obscured when there
is an equity stake in the small company or
if a company sponsors an academic to run
the study. Nonetheless, this trend begs
the question: why is the pharmaceutical
industry hesitant to explore cell-based
therapy? Significant factors may include
the following: insufficient demonstrationell 6, June 4, 2010 ª2010 Elsevier Inc. 517
Table 1. Timeline of Large Pharma Activity in Regenerative Medicine
Drug Modifiers
of Stem Cells Autologous Adult Stem Cells Allogenic Adult Stem Cells ESCs/iPSCs
Company LC EI LC EI LC EI LC
Pfizer 01/09: ViaCyte
(Diabetes)
06/08:
Eyecyte (eye)
12/09:
Athersys
(IBD)
04/09: UCL
(eye)
Novartis 03/09: Epistem
11/09: HSCI
(CNS)
11/09:
Cellerix (GI)
08/09: Opexa
(MS)
11/06: ESCs
(CNS)
Roche 06/09: I-STEM
(CNS)
11/09: Cellerix
(GI)
Sanofi Aventis 04/10: CureDM
(Diabetes)
Johnson &
Johnson
08/05: Tengion
(Bladders)
07/02:
Neuronyx 06/06:
Viacell (CV)
04/07: ViaCyte
(Diabetes)
Amgen 08/03: Viacell
(Cord blood
bank)
Novo Nordisk 07/08: Allocure
(AKI)
10/08: Cellartis
(Diabetes)
Teva (Generics
Company)
12/09: MGVS
(PVD)
07/05:
Proneuron
(SCI)
02/05:
Gamidacell
(Transplant)
09/07: CellCure
(eye)
06/07:
Technion (ESC)
Medtronic
(Device
Company)
04/08: Scil
(Dental)
11/07:
Arteriocyte
(Ischemia)
Smith & Nephew
(Device
Company)
10/07:
REMEDI
(Orthopedic)
Abbreviations are as follows: EI, date of equity investment made in company; LC, date of collaboration or licensing deal made with company; AKI,
acute kidney injury; CNS, central nervous system; CV, cardiovascular; GI, gastrointestinal; HSCI, Harvard StemCell Institute; IBD, inflammatory bowel
disease; MGVA, multigene vascular systems; MS, multiple sclerosis; PVD, peripheral vascular disease; SCI, spinal cord injury; UCL, University College
London. Note thatMerck, GSK, Abbott, AstraZeneca, Lilly, Bayer, BMS, Takeda show no public activity pursuing cell-based therapeutics, butmost are
pursuing stem cells as tools for enabling R&D. Source: EvaluatePharma (5/09 and generics excluded fromRx) for 2014 revenue projections and data on
Regenerative Medicine activity from public data searches primarily from company websites.
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Forumof efficacy, regulatory, and safety con-
cerns; a belief that cell therapies will not
offer substantial benefit over existing
therapies or demonstrate uptake by
patients; and lack of familiarity with both
the business model for commercializing
cell-based products and the complexity
of developing a product. Therefore, to
date, few large pharmaceutical compa-
nies are actively conducting clinical trials
given the challenges outlined above. For
pharmaceutical companies to move into
the commercialization of cellular regener-
ative medicine products, a ‘‘tipping point’’
needs to be reached, and the barriers
facing this industry will be dependent on
the type of cell-based approach under
development.
Of the existing clinical trials using stem
cells (Table 2), themajority have relied and518 Cell Stem Cell 6, June 4, 2010 ª2010 Elscontinue to rely on autologous cells, for
example, the patients’ own bone
marrow-derived mesenchymal stromal
cells (MSCs). This therapeutic approach
typically focuses on cellular induction of
immune modulation or tissue regenera-
tion rather than cell replacement and is,
therefore, amenable to investigator-spon-
sored studies given the low cost and
minimal technical capabilities required
for the trials. One area of active research
has been the application of autologous
humanMSCs for acute myocardial infarc-
tion, where cells are delivered directly to
the ischemic cardiac tissue. Numerous
trial designs have resulted in hundreds
of patients being treated to date. The
meta-analysis from collective clinical
data suggest MSCs show a modest, yet
significant, improvement in functionalevier Inc.markers, such as left ventricular ejection
fraction (LVEF), with reduction in left
ventricular end-systolic volume and lesion
area (reviewed in Abdel-Latif et al., 2007,
Martin-Rendon et al., 2008). Therefore,
the data suggest that autologous stem
cell therapy in cardiac disease results in
improved cardiac functioning outcomes.
However, the field will need more
adequately powered, randomized trials
to demonstrate clinical outcomes (e.g.,
mortality benefit) and extended clinical
assessments of patient outcomes in order
to become a standard of care. As autolo-
gous stem cell therapy becomes a reliable
treatment in ischemic, inflammatory, or
autoimmune diseases, biopharmaceuti-
cal companies will evaluate business
models to determine the commercial
opportunity associated with investment.
Table 2. Current Pipeline of Cell-Based Therapies in Development
Clinical Phasea
Cell-Based
Therapies
Company-Sponsored
Therapies
Proportion of Company-
Sponsored Therapies (%)
Large Company-Sponsored
Therapies
Phase I 38 35 92 0
Phase II 24 22 92 3 (Teva, Baxter, Genzyme)
Phase III 6 5 83 0
Total 68 62 91 3 (5%)
Disease-Specific Viewb
Disease Trials Company Sponsored
Trials
Proportion of Company
Sponsored trials (%)
Large Companies
Cardiac Disease 117 24 20 1 (Baxter)
Autoimmune Disorders 60 6 10 1 (Genzyme)
Endocrine/Metabolic 43 11 26 1 (Genzyme)
CNS 43 7 16 0
Total 263 48 18% 1%
aADIS Insight database search using cell replacement therapy as the search parameter with Phase I/II trials put in Phase I bucket and Phase II/III trials
placed in Phase II bucket.
b From clinicaltrials.gov. Search parameters used were ‘‘Cardiac Stem Cell,’’ ’’Autoimmune Stem Cell,’’ ‘‘Endocrine Stem Cell,’’ and ‘‘Nervous System
Stem Cell’’ with additional parameters of ‘‘NOT tumor,’’ ‘‘NOT cancer,’’ and ‘‘NOT proliferative disorder’’ used to winnow out oncology-related trials.
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cell-based therapies can be cost effec-
tive. For example, a recent analysis of
stem cell-derived bladder replacement in
the UK demonstrated a cost benefit of
£36,000 over existing therapies. Creating
therapies for each individual is a very
different business from pharma’s normal
operating model, in that each patient
becomes a lot of 1 and entails significant
logistical challenges (Smith, 2009).
Companies considering this opportunity
will need to evaluate if there are sufficient
patients requiring one cell replacement to
develop a scaleable process. Two
feasible commercial approaches to autol-
ogous cell therapy have been taken:
a centralized and distributed model. Tige-
nix have developed a centralized cell
production approach for ChondroCelect,
an approved therapy for cartilage repair
in Europe. A centralized model requires
patients to travel to a specialized center
for treatment. An alternative is the distrib-
uted model, in which cells are removed
from patients and isolated locally by
means of a device before being reintro-
duced to the patient. In this model,
patients are treated on site and are not
required to travel to a specific dedicated
center for treatment. The Cytori Celution
device allows bedside isolation of mesen-
chymal stem/stromal cells derived from
adipose tissue following liposuction.
These cells are then available for readmi-
nistration to patients for cosmetic andreconstructive surgery in Europe and
Asia. Cytori’s autologous MSCs are also
in clinical trials for autologous treatment
of acute and chronic heart disease. This
organization recently partnered with GE
Healthcare for the distribution of the Celu-
tion devices and commercialization of
stem cell banking and research markets.
Even if a significant proportion of the
registered autologous stem cell clinical
trials underway/completed show efficacy,
several hurdles must be overcome to
bring this approach into pharma’s
commercial sphere. Closed-loop devices
(sterile, transportable, single-use produc-
tion units) that simplify cell isolation and
expansion and preclude using costly
GMP facilities may be necessary.
Evidence that efficacy and/or safety
profiles are superior to existing traditional
small molecule or biologic therapies will
be required to justify the likely high cost
of goods and the subsequent selling
price. Regulatory oversight will depend
on the level of manipulation (e.g., drug
treatment, expansion, etc.) of the autolo-
gous cells. Nevertheless, recognition
that future opportunities exist in this area
is evidenced by licensing and invest-
ment by biopharmaceutical companies
(Table 1).
Human adult and umbilical/placental-
derived stem cell sources are being
developed as allogeneic cell-based thera-
pies. Current allogeneic stem cell-based
approaches are not typically designed toCell Stem Cengraft and rely on a variety of mecha-
nisms to deliver efficacy, including secre-
tion of paracrine factors prior to immune
destruction. Therefore, the mechanism
of action is not dissimilar to autologous
approaches. There are, however, data
that suggest that human MSCs may not
illicit an allogeneic immune response
when delivered therapeutically (Klyush-
nenkova et al., 2005). Therefore, the
potential exists to treat thousands of
patients with expanded adult stem cells
from a single donor. True replacement
and integration using allogeneic cells will
require re-education of the host’s immune
system, some type of immune suppres-
sion treatment, or HLA matching prior to
treatment. Treatment with immunosup-
pressive therapy can be done today but
is not a preferred option, while the other
options do not seem likely in the short
term. A robust understanding of the ther-
apeutic areas where adult progenitor cells
have clinical efficacy is likely to emerge
over the next few years. The majority of
studies being pursued in the clinical trials
database use mesenchymal stem cells or
multipotent adult progenitors for treat-
ment of immune disorders, given their
anti-inflammatory and immune-modifying
properties (reviewed in Uccelli et al.,
2008). Although adult stem cell ap-
proaches have been documented as
safe thus far, further studies using hu-
man adult stem cells will be required
to demonstrate efficacy in immune orell 6, June 4, 2010 ª2010 Elsevier Inc. 519
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Foruminflammatory conditions. While promising
data has been reported (albeit only in
press releases) by Osiris/Genzyme for
multiple indications, including GvHD, this
and other partnerships (e.g., Pfizer/
Athersys in inflammatory bowel disease)
will help define the opportunity for adult
allogeneic cell therapy. In terms of stimu-
lating wound repair and treating critical
limb ischemia and myocardial infarction,
as with autologous cell trials, modest
benefits have already been observed,
and many others studies have yet to
conclude. As a business model, alloge-
neic cell sources are more aligned with
the pharmaceutical business practice of
centralized product production and distri-
bution to health care providers. However,
for pharma to aggressively adopt alloge-
neic adult cell therapy, multiple issues
will need to be addressed, including cell
expansion and manufacturing, product
consistency, product delivery to the
patient, and successful well-designed,
well-controlled clinical trials showing
significant benefits over standard of
care. Given that cell-based therapies are
already available (e.g., Apligraf from
Organogenesis), this set of challenges is
not insurmountable but will require addi-
tional investment to minimize the cost of
making the cell therapy and providing it
routinely at the point of care.
Direct involvement from pharma in
human ESC therapy has been modest.
Concerns regarding the use of a human
ESCs notwithstanding, there are advan-
tages of using pluripotent stem cells as
source material for therapy because all
cell types are theoretically possible for
expansion and use in cell replacement
therapies. Examples include the encap-
sulated beta-cells for treatment of type 1
diabetes as proposed by ViaCyte
(formerly Novocell) and supported by
J&J’s equity stake, Geron’s oligodendro-
cyte therapy for spinal cord injury, and
Pfizer’s collaboration with University
College London to produce retinal
pigment epithelium for the treatment of
age-related macular degeneration.
Concerns around safety, anticipated
regulatory complexity, and lack of experi-
ence in this new area of research may be
significant barriers to entry. While iPSCs
may remove ethical concerns, the safety
and regulatory hurdles remain undimin-
ished and may even be greater. Much
research needs to be done to show that520 Cell Stem Cell 6, June 4, 2010 ª2010 Elsthe myriad of ways of generating iPSCs
do everything that the gold standard of
hESCs do—and no more—but the data
have thus far been mixed (Rowntree and
McNeish, 2010).
Conclusion
Commercially, any approach can be
viable if two major hurdles are overcome:
overall cost of the product and significant
patient-benefits. As payers implement
more rigorous health economic analysis
in decision-making, truly restorative or
disease-modifying therapies will offer
greater value and subsequent reimburse-
ment value over palliative ones. Cell-
based therapies move us toward this
goal, although currently launched prod-
ucts (e.g., Dermatology and Orthopaedic
focused) have been limited commercially
due to their inability to show significant
efficacy benefits over standard of care,
particularly as related to the costs of
cell-based therapies relative to the cost
of standard of care. pharma is moving
gradually into stem cells, first using tools
for traditional drug discovery, enhanced
by the greater availability of cell types
through iPSC technology. The opportu-
nity to generate novel molecules that
modify endogenous stem cells is very
much in scope and will likely lead to new
therapeutic approaches using small
molecules and biologics to enhance the
body’s natural repair mechanisms. These
are near-term options and need little
change in the way that pharmaceutical
industry works today. The move to true
cell-based therapeutics by pharma is still
modest. Some companies have preferred
to take equity stake in active biotech
companies while others are adopting
a ‘‘watchful waiting’’ approach until the
myriad of clinical trials currently underway
read out definitively one way or another
before actively investing in the space.
As there are hundreds of regenerative
medicine-focused biotechnology compa-
nies globally, it is expected that partner-
ships with biopharmaceutical companies
will develop following the demonstra-
tion of clinically safe and efficacious
approaches. Pfizer and Teva have taken
a much more proactive ‘‘partner and
learn’’ approach, and it is highly likely
that some companies may have stealth
efforts that are not yet visible in the public
domain. We still do not know whether
regenerative medicine will provide nicheevier Inc.benefit or will revolutionise healthcare. If
the latter, pharma needs to be prepared
for investment and change. Should signif-
icant benefit be demonstrated by stem
cell-based medicine, one must anticipate
a flurry of acquisitions and partnering
deals to make way for the future.WEB RESOURCES
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